Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Zachary J. Brown, Bernd Heinrich, Tim F. Greten
Nature Reviews Gastroenterology & Hepatology (2018) Vol. 15, Iss. 9, pp. 536-554
Closed Access | Times Cited: 202

Showing 1-25 of 202 citing articles:

The JAK/STAT signaling pathway: from bench to clinic
Xiaoyi Hu, Jing Li, Maorong Fu, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1370
β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
Marina Ruiz de Galarreta, Erin Bresnahan, Pedro Molina-Sánchez, et al.
Cancer Discovery (2019) Vol. 9, Iss. 8, pp. 1124-1141
Open Access | Times Cited: 661
Advances in molecular classification and precision oncology in hepatocellular carcinoma
Sandra Rebouissou, Jean‐Charles Nault
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 215-229
Open Access | Times Cited: 424
IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Li-Chuan Chan, Chia‐Wei Li, Weiya Xia, et al.
Journal of Clinical Investigation (2019) Vol. 129, Iss. 8, pp. 3324-3338
Open Access | Times Cited: 290
Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy
Yao Liu, Zhenzhen Xun, Kun Ma, et al.
Journal of Hepatology (2023) Vol. 78, Iss. 4, pp. 770-782
Closed Access | Times Cited: 287
Gut microbiome in HCC – Mechanisms, diagnosis and therapy
Robert F. Schwabe, Tim F. Greten
Journal of Hepatology (2020) Vol. 72, Iss. 2, pp. 230-238
Open Access | Times Cited: 269
Hepatic stellate cells suppress NK cell-sustained breast cancer dormancy
Ana Luísa Correia, Joao C. Guimaraes, Priska Auf der Maur, et al.
Nature (2021) Vol. 594, Iss. 7864, pp. 566-571
Closed Access | Times Cited: 219
Metabolic rearrangements in primary liver cancers: cause and consequences
Letizia Satriano, Monika Lewińska, Pedro M. Rodrigues, et al.
Nature Reviews Gastroenterology & Hepatology (2019) Vol. 16, Iss. 12, pp. 748-766
Closed Access | Times Cited: 195
Animal models for liver disease – A practical approach for translational research
Yulia A. Nevzorova, Zoé Boyer-Díaz, Francisco Javier Cubero, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 2, pp. 423-440
Open Access | Times Cited: 189
Combined locoregional-immunotherapy for liver cancer
Tim F. Greten, Michal Mauda‐Havakuk, Bernd Heinrich, et al.
Journal of Hepatology (2019) Vol. 70, Iss. 5, pp. 999-1007
Open Access | Times Cited: 179
Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
Bridget P. Keenan, Lawrence Fong, Robin Kate Kelley
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 175
The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications
Jiajie Hou, Haiyan Zhang, Beicheng Sun, et al.
Journal of Hepatology (2019) Vol. 72, Iss. 1, pp. 167-182
Open Access | Times Cited: 153
Neutrophils as potential therapeutic targets in hepatocellular carcinoma
Daniel Geh, Jack Leslie, Rob Rumney, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 4, pp. 257-273
Closed Access | Times Cited: 149
The landscape of gene mutations in cirrhosis and hepatocellular carcinoma
Miryam Müller, Thomas G. Bird, Jean‐Charles Nault
Journal of Hepatology (2020) Vol. 72, Iss. 5, pp. 990-1002
Open Access | Times Cited: 141
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, et al.
Hepatology (2021) Vol. 74, Iss. 5, pp. 2652-2669
Open Access | Times Cited: 126
Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD
Simon Wabitsch, Justin McCallen, Olena Kamenyeva, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 748-760
Open Access | Times Cited: 97
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, et al.
Cancer Communications (2023) Vol. 43, Iss. 4, pp. 455-479
Open Access | Times Cited: 77
Neutrophils in Cancer immunotherapy: friends or foes?
Xueqin Huang, Eugenie Nepovimová, Vojtěch Adam, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 32
Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation
Cédric Peleman, Sven Francque, Tom Vanden Berghe
EBioMedicine (2024) Vol. 102, pp. 105088-105088
Open Access | Times Cited: 15
pir-hsa-216911 inhibit pyroptosis in hepatocellular carcinoma by suppressing TLR4 initiated GSDMD activation
Zhouxiang Liao, Lichao Yang, Xiaojing Cheng, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma
Man Liu, Jingying Zhou, Xiaoyu Liu, et al.
Gut (2019) Vol. 69, Iss. 2, pp. 365-379
Closed Access | Times Cited: 142
Epitranscriptomics in liver disease: Basic concepts and therapeutic potential
Zhicong Zhao, Jiaxiang Meng, Rui Su, et al.
Journal of Hepatology (2020) Vol. 73, Iss. 3, pp. 664-679
Open Access | Times Cited: 126
Cancer models in preclinical research: A chronicle review of advancement in effective cancer research
Humna Sajjad, Saiqa Imtiaz, Tayyaba Nооr, et al.
Animal Models and Experimental Medicine (2021) Vol. 4, Iss. 2, pp. 87-103
Open Access | Times Cited: 100
TGF-β as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives
Serena Mancarella, Antonio Cigliano, Annarita Chieti, et al.
Seminars in Liver Disease (2018) Vol. 39, Iss. 01, pp. 053-069
Closed Access | Times Cited: 98
Diet-Induced Models of Non-Alcoholic Fatty Liver Disease: Food for Thought on Sugar, Fat, and Cholesterol
James M. Eng, Jennifer L. Estall
Cells (2021) Vol. 10, Iss. 7, pp. 1805-1805
Open Access | Times Cited: 98
Page 1 - Next Page

Scroll to top